IRCT20190303042892N1 IRCT 2019-03-11 Rasht University of Medical Sciences The effect of co-administration of quercetin supplemented cardiac cardiovascular system with cardiotoxicity of doxorubicin in patients with breast cancer Cardioprotective effect of quercetin supplement in against of cardiac induced toxicity of doxorubicin in breast cancer patients: a randomized, double-blined, placebo-controlled trial. 2018-05-16 anticipated 100 Complete https://irct.ir/trial/38024 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Limited Randomization is done in which both groups have the same sample size and the random allocation rule is also used to balance the number of people assigned to each group. For this purpose, SAS software and websites www.graghpad.com/quickcalcs/index.cf are used. Moreover, the SNOSE method is used to hide the allocation, the use of non-transparent sealed packets with random sequences, Blinding description: In this randomized clinical trial , placebo-controlled (Phase II), which is done in double blind (all patients and researchers are blinded to studying),of 100 women with breast cancer (C50-C50 disease code) ; Malignant neoplasm of breast). With the initial diagnosis and referral to the Behesht Clinic of Rasht in year 2018, which will be treated with anthracycline (doxorubicin) will be used. 2 Patients with Breast Cancer. Intervention 1: Intervention group: Patients in the intervention group receiving oral quercetin supplementation. Oral supplementation Quercetin (pure America manufacturer) continues 2 weeks before starting a chemotherapy dose of 250 mg (once a day) from the beginning and end of the chemotherapy (3 months) period. Intervention 2: Control group: the patients in the control group who received two They will receive a placebo week before the end of the course. Oral supplements of quercetine and placebo are similar in appearance, color and odor. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is I do not currently have the authority to publish it.